GPGabriele Pesarini

Gabriele Pesarini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gabriele Pesarini has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 10 March 2016
      • Vol. 64  (4) , 404-10

    Immediate and long-term clinical performance of bioresorbable vascular scaffolds in a real world population.

    by Silvia Maggio, Claudia Zanetti, Gabriele Pesarini, Carlo Zivelonghi, Anna Piccoli, Alessia Gambaro, Roberto Scarsini, Magdalena Cuman, Corrado Vassanelli, Flavio Ribichini

    The aim of this study was to evaluate the safety and efficacy of bioresorbable vascular scaffolds (BVS) in terms of acute success and long-term clinical events in a real world population according to the most updated technical recommendations. Perspective, single-center registry involving symptomatic patients treated with BVS from February 2013 to January 2016. Primary end-point was the occurrence of MACCEs at one year: death, target vessel related myocardial infarction, target vessel revascularization, stroke, major bleeding. Secondary endpoints were acute device and procedural clinical success, and occurrence of MACCEs at long-term follow-up. In total, 112 patients were treated on 173 lesions. Average age was 55.53±12.4 years and acute coronary syndrome was the admission diagnosis for 79.5% patients. Nine patients presented cardiac allograft vasculopathy after cardiac transplantation. Multi-vessel disease was treated in 50% of cases. Predilatation and post-dilatation were performed respectively in 96% and 88.4% of lesions. Intravascular imaging was used in 41 patients (37%). Angiographic success rate and procedural success rate were 100% and 97.3% respectively. Clinical follow-up was completed in 100 patients with an average follow-up of 10.5±8.3 months. Including peri-procedural and in-hospital MACCEs, target vessel failure was noticed in 7% of patients in the first year of follow up and in 11% of patients at long-term follow-up. Two cases of target lesion revascularization occurred 25 and 26 months after the index procedure. No cases of definite stent thrombosis were reported. Strict adherence to expert recommendation for BVS placement may minimize device related peri-procedural and mid-to-long term MACCEs in a real world population.

  • TCT-669 Clinical and economic outcomes of TAVI vs. Balloon Aortic Valvuloplasty as a “bridge” therapy: a single-center experience

    by Flavio L. Ribichini, Gabriele Pesarini, Mattia Lunardi, Carlo Zivelonghi, Corrado Vassanelli

  • Echo-doppler and invasive evaluation of valvulo-arterial impedance in patients with severe aortic stenosis: impact of pressure recovery

    by Corinna Bergamini, Giorgio Golia, Aldo D. Milano, Matteo Pernigo, Francesca Vassanelli, Gabriele Pesarini, Giuseppe Faggian, Corrado Vassanelli

  • Transcatheter Tricuspid Valve Implantation by Femoral Approach in Trivalvular Heart Disease

    by Flavio Ribichini, Gabriele Pesarini, Mauro Feola, Marco Agostini, Gionata Molinari, Andrea Rossi, Giuseppe Faggian, Corrado Vassanelli


  • Late and very late coronary stent thrombosis: Intravascular ultrasound findings and associations with antiplatelet therapy

    by Gabriele Pesarini, Rajesh Dandale, Antonio Rigamonti, Michele Pighi, Carlo Zivelonghi, Antonio Mugnolo, Valeria Ferrero, Corrado Vassanelli, Flavio Ribichini

    Background and Objective: Late and very‐late stent occlusion remains a serious complication of coronary stenting. Despite their high anti‐restenotic efficacy, drug‐eluting stents (DES) have been associated to more late‐thrombosis as compared to bare‐metal stents (BMS). The aim of this study is to analyze the clinical presentation, angiographic, and intravascular ultrasound (IVUS) findings in patients with late or very late stent thrombosis and the relationship with the antiplatelet regimen.Methods and Results: Between January 2007 and December 2011, 34 consecutive patients with clinical syndromes compatible with late or very‐late stent occlusion were studied with IVUS during emergency catheterization; 25 had DES and 9 had BMS. Thrombotic total occlusion was more common in DES (16 = 64%) than BMS patients (2 = 22%; P = 0.02) and ST‐segment elevation myocardial infarction was the predominant clinical presentation in the former group (60% compared to 22%; P = 0.05). The time elapsed between implantation and failure was much longer in DES patients: 33 ± 22 versus 17 ± 14 months for BMS; P = 0.05. IVUS analysis showed a higher incidence of incomplete stent apposition (ISA) in the DES group compared to the BMS group (56% vs. 11%; P = 0.005) and in‐stent plaque rupture was the most common finding in the BMS group (78%). In DES group, ISA was found more frequently in patients still under dual antiplatelet therapy (71%).Conclusions: Very late DES failure often causes ST‐elevation myocardial infarction; these very late events may not correlate with the interruption of antiplatelet therapy. Severe, late acquired ISA belongs to DES and is frequently observed in patients with very late DES thrombosis.


  • Effects of prednisone on biomarkers of tubular damage induced by radiocontrast in interventional cardiology

    by Flavio Ribichini, Alessia Gambaro, Michele Pighi, Gabriele Pesarini, Pietro Manuel Ferraro, Cecilia Zuppi, Silvia Baroni, Romina Penitente, Valeria Ferrero, Corrado Vassanelli

    Contrast-induced nephropathy (CI-AKI) is a complication of diagnostic/therapeutic hemodynamic procedures in cardiology, which may also cause renal cholesterolinic atheroembolism. Despite the severe clinical impact of these complications, there is no optimal therapy for preventing and treating them. We suggest a short course of high-dose steroids as an effective preventive measure.


    • 1 March 2009
      • Vol. 21  (3) , 86-91

    Steroid-eluting stents in patients with acute coronary syndromes. Angiographic results of DESIRE: Dexamethasone-Eluting Stent Italian REgistry.

    by Gabriele Pesarini, Valeria Ferrero, Fabrizio Tomai, Leonardo Paloscia, Nicoletta De Cesare, Corrado Tamburino, Federico Piscione, Francesca Vassanelli, Flavio Ribichini

    Steroids have known powerful anti-inflammatory effects. This study was designed to assess the possible antiproliferative action of the Dexamet(R)dexamethasone-loaded stent. This was a prospective, controlled registry performed in 20 Italian centers that enrolled 332 patients with acute coronary syndromes (ACS) treated according to an early-invasive approach with the implantation of 420 dexamethasone-eluting stents in 387 coronary lesions. Six of the enrolling centers participated in the angiographic substudy: elective 6-month follow-up angiography was performed in 140/151 patients (92.7%). Quantitative coronary analysis (QCA) was performed at a centralized core laboratory on 156 lesions treated with the Dexamet stent. One hundred forty patients (156 lesions) underwent elective QCA. Patients presented with either unstable angina (80%) or Non-ST-elevation myocardial infarction (20%); 70 patients (50%) had ST-T segment changes, 81 (58%) had troponin elevation and 31 (22.1%) were diabetic. One hundred twenty-five patients had a single lesion, 117 of which were treated with a single stent, while 8 received multiple stents. Mean lesion and stent lengths were 11.94 +/- 6.30 and 17.30 +/- 6.08 mm, respectively. In-segment binary restenosis (percent [%] diameter stenosis >/= 50%) was 34.3% per patient (48/140), or 33.3% per lesion (52/156); the mean late lumen loss was 0.95 +/- 0.64 mm in-stent and 1.02 +/- 0.59 mm in-segment. At multivariate analysis, baseline minimum luminal diameter (MLD) (MLD - odds ratio [OR] = 0.18; 95% confidence interval [CI] = 0.04-0.72; p = 0.01) and lesion length (OR = 1.12; 95% CI = 1.04-1.2; p < 0.01) were independent predictors of 6-months binary restenosis This is the first large, multicenter analysis of the angiographic outcome obtained with Dexamet. Our results do not support any effective antiproliferative action of this device implanted in patients with ACS.